GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iRadimed Corp (NAS:IRMD) » Definitions » EBIT

iRadimed (iRadimed) EBIT : $20.78 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is iRadimed EBIT?

iRadimed's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $4.75 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $20.78 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. iRadimed's annualized ROC % for the quarter that ended in Mar. 2024 was 44.18%. iRadimed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 72.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. iRadimed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.12%.


iRadimed EBIT Historical Data

The historical data trend for iRadimed's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iRadimed EBIT Chart

iRadimed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.65 -0.76 9.82 15.63 20.04

iRadimed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.01 4.96 5.91 5.16 4.75

Competitive Comparison of iRadimed's EBIT

For the Medical Devices subindustry, iRadimed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iRadimed's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where iRadimed's EV-to-EBIT falls into.



iRadimed EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iRadimed  (NAS:IRMD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

iRadimed's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=18.992 * ( 1 - 21.11% )/( (29.433 + 38.393)/ 2 )
=14.9827888/33.913
=44.18 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

iRadimed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=18.992/( ( (11.332 + max(10.34, 0)) + (11.39 + max(19.561, 0)) )/ 2 )
=18.992/( ( 21.672 + 30.951 )/ 2 )
=18.992/26.3115
=72.18 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.224 + 12.821 + 1.194) - (12.961 + 2.57 + 0.368)
=10.34

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(13.027 + 12.696 + 1.036) - (4.494 + 2.338 + 0.366)
=19.561

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

iRadimed's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=20.776/504.158
=4.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iRadimed EBIT Related Terms

Thank you for viewing the detailed overview of iRadimed's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


iRadimed (iRadimed) Business Description

Traded in Other Exchanges
Address
1025 Willa Springs Drive, Winter Springs, FL, USA, 32708
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold primarily to hospitals and acute care facilities in the United States and internationally.
Executives
Roger E. Susi director, 10 percent owner, officer: CEO, President, Chairman C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
James B Hawkins director C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Anthony Vuoto director
Monty K Allen director
Hilda Frederique Scharen-guivel director 440 PALM ISLAND SE, CLEARWATER BEACH FL 33767
John Glenn officer: Chief Financial Officer 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
Christopher K. Scott officer: CHIEF FINANCIAL OFFICER & SECR C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Brent Johnson officer: Exec. VP. Sales & Marketing 4900 HOPYARD RD, SUITE 210, PLEASITAN CA 94588
Steven M. Nardi officer: VP MANUFACTURING C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Louis S. Waldman officer: CONTROLLER C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Leslie L Mcdonnell director, officer: Chief Exec Officer & Director 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Francis X. Casey officer: VP OF REG AND QUAL ASSURANCE C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
John K Mccreery officer: Chief Operating Officer IRADIMED CORP, 1025 WILLA SPRINGS BLVD, WINTER SPRINGS FL 32708
Jonathan Kennedy director INTERSIL CORPORATION, 1001 MURPHY RANCH ROAD, MILPITAS CA 95035
Serge Novovich director C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708

iRadimed (iRadimed) Headlines

From GuruFocus

IRADIMED CORPORATION Issues Urgent Medical Device Correction

By sperokesalga sperokesalga 02-24-2023

Insider Alert: An Insider Just Sold iRadimed Corp Shares

By GuruFocus Research GuruFocus Editor 05-18-2023

RESOURCE CONSULTING GROUP INC Buys 2, Sells 3 in 2nd Quarter

By GuruFocus Research GuruFocus Editor 07-11-2022

IRADIMED Names John F. Glenn Chief Financial Officer

By GuruFocusNews GuruFocusNews 06-05-2022

IRADIMED Names John F. Glenn Chief Financial Officer

By GuruFocusNews GuruFocusNews 07-05-2022